Publications by authors named "A M Miscio"
Introduction: Although migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly CM patients.
Methods: This is a post hoc analysis of real-life prospectively collected data at 16 European headache centers on CM patients treated with OBT-A over the first three treatment cycles (i.
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors.
Int J Environ Res Public Health
September 2022
Article Synopsis
- The study focused on identifying chronic migraine patients who might benefit the most from onabotulinumtoxinA treatments, analyzing response rates in a multicenter European setting.
- Excellent responders were categorized as those with either a significant drop in headache days (≥75%) or those experiencing infrequent headaches (<4 days/month), with about 10% and 5% of patients classified in each category, respectively.
- Key findings indicated that excellent responders tended to have higher medication overuse and that female patients were less likely to be categorized as frequency-based excellent responders, suggesting that those without medication overuse or female patients might see less benefit from the treatment.
Introduction: Migraine is mostly a female disorder because of its lower prevalence in men. Less than 20% of patients included in the available studies on migraine treatments are men; hence, the evidence on migraine treatments might not apply to men. The aims of the present study were to provide reliable information on the effectiveness of onabotulinumtoxinA (BT-A) for chronic migraine in men and to compare clinical benefits between men and women.
View Article and Find Full Text PDFIntroduction: OnabotulinumtoxinA (BT-A) quarterly was the first treatment approved specifically for chronic migraine (CM). It is unclear whether three cycles are better than two to assess early BT-A response.
Methods: We performed a retrospective analysis on real-life prospectively collected data in 16 European headache centers.
Introduction: OnabotulinumtoxinA (BoNT-A) was proved effective and safe in chronic migraine (CM) prevention by the Phase III Research Evaluating Migraine Prophylaxis (PREEMPT) and Phase IV Chronic migraine OnabotulinuMtoxinA Prolonged Efficacy open-Label (COMPEL) trials over 1 and 2 years of treatment, respectively. Real-life studies highlighted BoNT-A sustained benefits up to 3 years of administration. Aim of this retrospective real-life study was observing within a 4-year timeframe the progress of a consecutive series of CM patients treated with BoNT-A and evaluating whether long-term quarterly treatment (up to 16 cycles) confirms the outcomes of previous studies over shorter periods of therapy.
View Article and Find Full Text PDF